论文部分内容阅读
[目的]探讨新型重组血管内皮抑制素(恩度)联合顺铂(DDP)腔内注射治疗癌性胸水的临床疗效和不良反应。[方法]随机对照观察46例恶性肿瘤并发胸水患者治疗情况,其中采用新型重组血管内皮抑制素(恩度)联合顺铂(DDP)腔内注射治疗21例为治疗组,单纯DDP治疗25例为对照组。[结果]治疗组和对照组总有效率(CR+PR)分别为61.90%、40%(u=3.48,P﹤0.05),差异有统计学意义。治疗组和对照组总的不良反应率分别为33.33%,28%;差异无统计学意义(χ2=0.83,P﹥0.05)。[结论新型重组血管内皮抑制素(恩度)联合顺铂(DDP)腔内注射治疗癌性胸水安全有效,可以作为临床上治疗癌性胸水选择方法之一。
[Objective] To investigate the clinical efficacy and adverse reactions of the new recombinant endostatin (Endostar) combined with cisplatin (DDP) for the treatment of cancerous pleural effusion. [Methods] 46 cases of malignant tumor complicated with pleural effusion were randomly divided into treatment group and 21 cases treated with new recombinant endostatin (Endostar) combined with cisplatin (DDP) intracavitary injection. The treatment of 25 cases with DDP alone Control group. [Results] The total effective rate (CR + PR) of the treatment group and the control group were 61.90% and 40%, respectively (u = 3.48, P <0.05). The difference was statistically significant. The total adverse reaction rates of the treatment group and the control group were 33.33% and 28% respectively, with no significant difference (χ2 = 0.83, P> 0.05). [Conclusion The new recombinant endostatin (Endostar) combined with cisplatin (DDP) intracavitary injection of cancer pleural effusion is safe and effective, which can be used as one of the clinical options for the treatment of malignant pleural effusion.